Global Clinical Development Partner

Providing Quality Clinical Research Solutions



veeda clinical research®

Table Of Contents

veeda clinical research®

The Veeda Advantage



veeda clinical research®

Corporate Overview

Evolution

Privately owned, board managed company

2004 — Founded at Shivalik with 37 Employees

2006 — First regulatory inspection from ANVISA

2007 — First regulatory inspection from WHO, US FDA & UK MHRA

2010 — New Facility at Insignia

2015 — New Facility at Vedant

2018
- New Facility at Skylar Exclusively for Screening
- CX Partners join

2019 — New Facility at Mehsana, Total number of Employees 970

2021
- New Phase 1 Facility at Vedant
- Biosimilar JV with Somru BioScience

Corporate Outlook

- Focus on Organic and Inorganic growth strategies to enhance service capabilities
- Financial Stability based on prudent management & Private Equity sponsorship
- Operational Stability based on experienced professional management and strong quality culture
- Ongoing investments in technology to enhance operating efficiencies and compliance management

Corporate Philosophy

Vision

In an industry where innovation is increasingly multifaceted and collaborative, we aspire to be the research partner of choice for innovative (bio)pharmaceutical companies worldwide for their critical product development programs.

Mission

To be the pre-eminent independent Indian contract research Organisation, with global execution capabilities, distinguished by the breadth of our services and by excellence in the quality of our : Scientific and regulatory knowledge; Research design, execution and insights; and Client centricity.

Our Values

- Honesty and Integrity
- Humility
- Openness
- Excellence
- Innovation
- Nurturing Individual Growth

Quality Structure

"Veeda's management is committed to continuous improvement in the effectiveness of our Quality culture, to providing quality research solutions that meet sponsor and regulatory requirements and to protecting the rights, safety and well being of the study volunteers"

- Comprehensive system with more than 350 SOPs
- QC & QA monitoring
- Monthly Quality Review Meetings
- CAPA Management

Focus on implementing policies & nurturing individual behavior to sustain our culture of quality

- Balanced Score Cards (BSC) for augmenting corporate strategy
- Quantifiable Performance Metrics for all departments
- Individual KPI's & KRA's linked to BSC
- Continuous process improvement

veeda clinical research

Regulatory Credentials

FDA	33*
ansm – Agence nationale de sécurité du médicament et des produits de santé	1
MHRA – Regulating Medicines and Medical Devices	3
AGES	1
ANVISA	14
mcc – Medicines Control Council	1
World Health Organization	5
DCGI	18
NPRA Malaysia	5

*FDA : 17 AUDITS FOR PATIENT BASED STUDIES
16 AUDITS FOR HEALTHY SUBJECTS STUDIES

Infrastructure

Clinical Infrastructure



VEDANT
Clinical, Bio-analytical facility

MAGNET CORPORATE PARK
Administrative office

SHIVALIK
Dedicated Clinical facility

MEHSANA
Clinical and Screening facility

SKYLAR
Common screening facility for both Shivalik and Vedant

INSIGNIA
Dedicated Bio-analytical facility

ARCHIVES
Internal archival area in each facility.
Separate long term archival facility at Changodar and Unjha

Spread across 14 clinics



Shivalik
170 Beds +
7 Special care beds +
12 **Intensively monitored beds** to conduct **Phase I** study

Vedant
170 Beds +
6 Special care beds +
18 **Intensively monitored beds** to conduct **Phase I** study

Mehsana
162 Beds +
7 Special care beds

veeda clinical research

Bioanalytical Infrastructure



- **46 LC-MS/MS** machines
  - Insignia - 33
  - Vedant - 13
  - **API 5500/4000/3200/3000/2000**
  - **Shimadzu 8060/8050/8040**
  - **Quattro Premier**
- **2 ICP-OES**
- **Watson LIMS**

Storage Capacity

Plasma Sample:
45 Deep freezers with capacity to store 11,25,000 samples at -80 C˚

IP Storage:

- 3 Walking type stability chambers with overall capacity to store 34000 Ltr for retention at room temperature
- 4 Humidity chambers with overall capacity of 3200 Ltr
- 4 Pharmaceutical refrigerators having storage capacity of 3550 Ltr at 2-8 C˚

Archival: Capacity to archive approximately 51000 files

veeda clinical research®

505(b)(2) Applications

505(b)(2) candidates

Type	Definition
1	New Molecular Entity (Pro-drug of previously approved drug)
2	New Active Ingredient (New salt, Racemate, Enantiomer, Complex)
3	New Dosage Form (Strength, route of administration, altered excipient, changes in release pattern, Drug device combination products)
4	New Combination / FDC
5	New Formulation or Other Differences (e.g., new indication, new applicant, new manufacturer, dosing regimen)
6	New Indication or Claim, Same Applicant
7	Previously Marketed But Without an Approved NDA
8	Rx to OTC (Previously approved drug changed to OTC or changes to existing OTC product)

Submission Classification



Reference: https://www.ncbi.nlm.nih.gov/pubmed/30616377

FDA submission classification of drug products approved via 505(b)(2) pathway from 2012 to 2016 (n : 224). Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements

Type of studies required

Since the 505(b)(2) pathway allows the use of public data or the FDA's previous findings in lieu of novel trial data, some **development programs** may conduct bridging studies that preclude the need for nonclinical or clinical studies, or both.

Establish a bridge between proposed drug product and each listed drug against which safety / efficacy to be proven.

Sufficient data are required to **support each difference**.

Bridging Approaches to support 505(b)(2) Applications



Clinical Studies	• Single & Multiple dose BA / BE • Dose proportionality • Pharmacokinetic / Pharmacodynamic • Food effect • Safety / Efficacy studies • Drug drug Interaction. • Single ascending dose / Multiple ascending dose.
Pre Clinical Studies	• Pre clinical
In Vitro Studies	• In vivo – Bio waiver • In vitro dose dumping studies • In vitro PD studies

Veeda CR – Expertise

veeda clinical research®

BA / BE Expertise

BABE studies: 3200+ including standalone Bioanalytical studies

1051 pilot / 1697 pivotal

Single dose / multiple dose

- Oral Dosage forms
  - -capsules/ tablets
  - - solutions/ suspensions
  - -ODT (Orally disintegrating tablets)
  - - Sublingual
  - - ODS (OroDispersible strip)
- Rectal
  - - Capsules
  - - Suppository
- Transdermal
  - - Patch
  - -cream
- Injectable
  - - IV Infusions
  - - I.M.
  - - S.C.
  - - LAI
- Hormonal
  - - Expertise in handling > 100 female volunteers during entire course of clinical conduct.
  - - Recruited 1700 female subjects in 45 Studies
- Inhalation
  - -pMDI
  - -Dry powder
  - -Nasal Spray

Special studies



PD studies Experience

- Single dose comparative bioavailability and **pharmacodynamic** study on Anticoagulant drug.
- Multiple-dose **Immunogenicity evaluation** study of Anticoagulant drug.
- Effect of a single oral dose of Quinolone Antimicrobial on **ventricular repolarization (QT/QTc interval prolongation)** in healthy male volunteers.
- Single dose study to assess safety, pharmacokinetics and **pharmacodynamics** of therapeutic proteins administered subcutaneously to healthy, adult, male subjects.
- A cross-over **pharmacodynamic study** to evaluate equivalence of corticosteroids (Inhalation product) in healthy, adult, male human subjects.
- A crossover study to compare the **systemic pharmacodynamic effects** of the corticosteroids (Inhalation product) in healthy, adult, male human subjects

Drug –Drug Interaction

- A Study to Assess the Effects of Multiple Oral Doses of calcium-channel blockers drug, a Moderate CYP3A4 Inhibitor, on the Single-Dose Pharmacokinetics of XYZ drug in Healthy Volunteers.
- A Study to Evaluate the Effect of Multiple Oral Doses of calcium-channel blockers drug on Single-Dose Pharmacokinetics of ABC drug in Healthy Volunteers.
- **Pharmacokinetic interaction** study when administered as FDC and co-administered as single tablets.

Dose Proportionality

- Availability of statistical model to perform dose proportionality assessment w.r.t. USFDA and EMA regulatory requirements.
- Performed dose proportionality studies:
  - dose proportionality assessment of oral glucocorticoids.
  - dose proportionality assessment of ABC.

Food effect study

In addition to the vast experience in conducting fasting and fed bioavailability / bioequivalence studies in line with regulatory requirements, Veeda CR has an expertise in handling specialized food effect studies. Some examples are as follow:

Two way crossover – oral bioavailability (pharmacokinetic comparison) studies under fasting and fed state of test formulations.

Studies to evaluate food effect of pharmacokinetics of test formulations as three way crossover design under different conditions as follow:

- high-fat, high-calorie breakfast
- sprinkled on one tablespoon of applesauce
- under fasting state with 240 mL of water

Two-Treatment, Three-Period, Six-Sequence, Crossover, Bioequivalence studies under fasting and fed conditions to assess the effect of food:

- Test formulation under fasting and fed states
- Reference formulation under fed condition

FIH

Safety and immunogenicity study of Polio Vaccine in healthy adult human male subjects.

Placebo-Controlled, Randomized, Double-Blind, Rising Single Dose Study of XYZ Drug to Evaluate Safety, Tolerability, Pharmacokinetics, and

Pharmacodynamics in Healthy, Adult Volunteers and Adult Type-II Diabetic Volunteers.

A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Oral Doses of XYZ Drug in Subjects with T2DM Treated with Metformin.

(Upcoming)

Pharmacokinetics, Safety and Tolerability study of XYZ Drug

Clinical Trials and Expertise

Patient based PK – BE studies

- >10 studies
- Number of patients: 24 – 108

Phase II / III studies

- 6 studies
- Therapeutic areas: Bone Diseases and oncology

Veeda CR - 505(b)(2) Experience

505(b)(2) Veeda experience

❖ **Veeda CR has been a partner in supporting 505(b)(2) applications with ~45 studies experience with various clients.**

505(b)(2)	Test	RLD	Design
Salt change	Drug **hemitartrate**. Tablets	Drug **mesylate** Tablets	Single dose BE
Change in formulation & dosage form	Drug **300mg ER tablets**	Drug **150 mg IR capsules (2x150mg)**	comparative BA
Change in formulation & strength	Drug **sublingual tablets** 0.6 mg	Drug **Tablets 1mg**	comparative BA
Change in formulation	Drug **ODT** 2 mg	Drug **Tablets** (2 mg)	Single dose BE

505(b)(2) Veeda experience

505(b)(2)	Test	RLD	Design
FDC	**Fixed dose Combination** of statin and cholesterol-lowering Agent	**Individual Formulations** of statin + cholesterol-lowering Agent	Single dose BE
FDC	**Fixed dose Combination** of statin and cholesterol-lowering Agent	**Individual Formulations** of statin + cholesterol-lowering Agent	Single dose BE
Change in formulation	Statin Drug oral **suspension** 20mg/5ml (total dose - 80 mg)	Drug **tablets**	Single dose BE
Change in formulation	Drug **20 mg Soluble Tablets**	Drug **Tablets 2.0 mg (2.0 mg X 10)**	Comparative PK Study
Strength change	Drug **600 mg** PR tab	Drug XR tablets **200 mg** (3 tablets X 200 mg)	Multiple dose BE

Recognitions

Celebrating 16 years of excellence in clinical research

2004

2017

Organization	Award Category
Praxis Media	National Excellence Award
AI Global	Best Pharmaceutical CRO
Health & Safety Awards	Best Clinical Research-India
Times Network	Best Clinical Research-India
Gujarat	Mark of Excellence
Frost & Sullivan	Indian Clinical Research company of the year

2018

Organization	Award Category
ASSOCHAM India	Best Clinical Research Organization - India
Health & Wellness	Clinical Trial Company of the Year
Economic Growth Foundation	Bharat Udhyog Ratan Award in Clinical Research

2019

Organization	Award Category
World Quality Congress & Awards	Best Quality Clinical Research Organization in India
Indian Pharma Expo & Business Excellence Awards	Best Quality Clinical Research Organization in India
2019	Indian Clinical Research company of the year

2020

Organization	Award Category
BioSpectrum	Top CLRO Company
Praxis Media	Best Quality Clinical Research Services in India

veeda clinical research

Thank You

veeda clinical research®

Partners in Creating a Healthier Tomorrow

For any further assistance kindly write to us at info@veedacr.com
www.veedacr.com